Overview
The Center for Maryland Advanced Ventures (CMAV) facilitates technology transfer for UM Ventures and amplifies the impact of university-based research. Strategic initiatives help identify research projects with strong commercial potential while providing programming that supports the advancement of technology commercialization. The initiatives are designed to integrate and work collaboratively with existing offerings from UM Ventures, TEDCO, and the Maryland Department of Commerce.

CMAV is directed by Jim Hughes, senior vice president and chief enterprise and economic development officer at University of Maryland, Baltimore (UMB).

History
Located on the UMB campus, CMAV was created and funded through the University of Maryland Strategic Partnership Act of 2016 and launched on July 1, 2017. The legislation provides $4 million annually to strengthen the commercialization of high-potential, university-based discoveries. Due to the success of the program, in FY2022, the legislature increased funding for CMAV by $2.5 million annually. Starting in FY2023, the program will operate with $6.5 million each year.

In Action
CMAV funds entrepreneurial staff, grants to startups and growing companies, program costs for promoting technology commercialization, matching support for faculty projects with high potential, student activities and experiences, outreach to the greater Baltimore scientific community, development of intellectual property, and assistance for small business formation. Throughout FY2022, the CMAV team focused on broadening outreach and developing additional programs that support emerging technologies and current areas of need. The following report illustrates the impact of CMAV funding, detailing annual and cumulative achievements of the programs supported by CMAV.
MARYLAND MOMENTUM FUND
FY2022 ACCOMPLISHMENTS

$2.5M INVESTED
6 INVESTMENTS IN NEW COMPANIES
6 INVESTMENTS IN EXISTING COMPANIES

A collaboration between UM Ventures and the University System of Maryland (USM), the Maryland Momentum Fund (MMF) is an early-stage investment fund that invests in Maryland-based, USM-affiliated startup companies.

To enhance the early success seen since the inception of MMF, in FY2022 the Board of Regents provided an additional $6 million in funding, taking the MMF from a $10 million fund to a $16 million fund. Investments from USM Institutions are projected to bring the total size of the MMF to over $21 million.

CMAV funds a full-time Managing Director based at UMB and provides additional support and operational expenses. The MMF staff conduct outreach at all USM institutions, soliciting applications for funding and providing advice and support to entrepreneurs across USM.

LIFETIME PORTFOLIO ACCOMPLISHMENTS

$10.6M INVESTED
28 PORTFOLIO COMPANIES
8 USM INSTITUTIONS

$91.1M MATCHED
150+ UNIQUE CO-INVESTORS
140 NEW JOBS CREATED
The Grid, located in UMB’s Health Sciences and Human Services Library (HS/HSL), has continued to expand its programming to provide entrepreneurial resources and education to students, faculty, staff, and the community. The Grid Pitch showcase welcomed 15 student teams and a total of 25 students, making it the largest applicant pool and accepted teams to date. It was hosted in-person for the first time since 2019, and more than 65 individuals from across UMB, Baltimore, and greater Maryland joined to celebrate student entrepreneurship.

The Grid’s virtual student incubator now works with six student companies in total. The Student Social Venture Fund also awarded two more students $2,500 and $5,000 seed grants to support their social impact ventures. These grants represent the first phase of a greater investment in early-stage social entrepreneurship by individual and institutional donors in Baltimore and beyond.

**PRESIDENT’S ENTREPRENEURIAL FELLOWSHIP**
To enhance entrepreneurial education, the President’s Entrepreneurial Fellowship program provides UMB and University of Maryland, College Park (UMCP) Robert H. Smith School of Business MBA students the opportunity to learn first-hand the unique challenges of commercializing life science technologies. Mentored by UM Ventures staff, the Fellows work on interdisciplinary teams to commercialize UMB-owned technologies.

In FY2022, five fellows, representing the School of Pharmacy, School of Dentistry, and the Robert H. Smith School of Business, were joined by two volunteer fellows from the previous year who were interested in an extended experience. The Fellows investigated companies focused on the tumor microenvironment and metastatic disease. They also worked under the mentorship of the Broth Agency, an advertising company which specializes in early life science company advising, on a project to develop a name for a new product being launched by a MMF portfolio company.

**GRADUATE RESEARCH INNOVATION DISTRICT**

**FY2022 ACCOMPLISHMENTS**

15 **STUDENT TEAMS FOR GRID PITCH**
40 **WORKSHOPS**
1K **PARTICIPANTS**

The Grid, located in UMB’s Health Sciences and Human Services Library (HS/HSL), has continued to expand its programming to provide entrepreneurial resources and education to students, faculty, staff, and the community.

The Grid Pitch showcase welcomed 15 student teams and a total of 25 students, making it the largest applicant pool and accepted teams to date. It was hosted in-person for the first time since 2019, and more than 65 individuals from across UMB, Baltimore, and greater Maryland joined to celebrate student entrepreneurship.
SMALL BUSINESS DEVELOPMENT CENTER

FY2022 ACCOMPLISHMENTS

483 CLIENTS COUNSELED  639 JOBS CREATED OR RETAINED  35 NEW BUSINESSES STARTED

$5.87M LOANS AND CAPITAL INFUSION INTO BALTIMORE CITY BUSINESSES

The Small Business Development Center, the Federal small business outreach entity, is supported with funding and space at UMB. The office provides direct assistance to local and University-affiliated entrepreneurs from a wide array of business sectors.

INTELLECTUAL PROPERTY LAW AND ENTREPRENEURSHIP CLINIC

FY2022 ACCOMPLISHMENTS

26 STUDENTS ENGAGED  86 CLIENTS SERVED  37 MINORITY OWNED/CO-OWNED 35 FEMALE OWNED

19 PATENT APPLICATIONS SUBMITTED  7 TRADEMARK APPLICATIONS FILED  19 TRADEMARK APPLICATIONS ISSUED

56 OTHER USPTO FILINGS FOR PENDING TRADEMARK APPLICATIONS  9 NEW MARYLAND LIMITED LIABILITY CORPORATIONS FORMED

The Francis King Carey School of Law Intellectual Property Law and Entrepreneurship Clinic (IPEC) provides second- and third-year law students with valuable work experience. Under the supervision of professors and with the support of two part-time clinical law instructors, students work with clients from UMB and the region to provide general counsel on basic business law, protect trade secrets, prepare nondisclosure agreements, and assist with company formation.

In Fall 2021, IPEC introduced a formal Business Law Track which enhanced the number and scope of services provided to clients, including drafting nondisclosure agreements, LLC operating agreements, and creating privacy policy statements for electronic communications.
Baltimore Fund

The Baltimore Fund encourages University-created or -sponsored technology companies to locate and expand in Baltimore City as specified in the legislation. CMAV funds the Director of the Baltimore Fund and all expenses of the program. In addition to managing the program, the Director facilitates engagement with Maryland’s entrepreneurial ecosystem and its myriad support programs and resources including TEDCO, Baltimore Development Corporation, and the Maryland Department of Commerce. The Baltimore Fund is open to all Maryland public higher education institutions and is administered by UMB.

Since the Fund’s creation:
• Baltimore Fund portfolio companies have raised over $10 million in investment and have sales exceeding $25 million.
• Awards have supported companies representing seven Maryland public higher education institutions and a wide array of technologies.
• Grants to Morgan State University, UMCP, UMB and IMET have directly supported their entrepreneurial activities in Baltimore City and increased outreach to diverse populations.

FY2022 activities included:
• Awards to five companies: Next Step Robotics, JuneBrain, RemBac, NAWEC, and Astek Diagnostics.
• Supporting nine new vendors in Lexington Market by providing a loan loss reserve to Baltimore Community Lending’s targeted microloan program.
• Supporting the expansion of UMCP’s I-Corps program in Baltimore City at Morgan, Coppin, and University of Baltimore.
• Investing in UpSurge, an organization focused on building Baltimore’s knowledge economy and reputation as a top tier innovation city. Their vision is to make Baltimore the country’s first Equitech city—a diverse and inclusive innovation community.

LIFETIME ACCOMPLISHMENTS

62 ENTITIES ASSISTED

640+ JOBS CREATED OR RETAINED

14 NEW LEASE SUBSIDIES

19 COMPANY EXPANSION AND RELOCATION GRANTS
FY2022

GRANT ACTIVITIES
GRANT APPLICATIONS
The legislation encourages the support of external grants to support and enhance CMAV activities. UMB submitted and participated in a number of grant applications to support the University’s translational research and the growth of Baltimore’s innovation ecosystem.

In addition to the direct commercialization grants mentioned in other parts of this report, the following grants were submitted and directly enhance CMAV funding, programming, and activities.

FY2022 Grant Applications
• U.S. Economic Development Administration’s (EDA) Build Back Better Regional Challenge
• National Science Foundation’s Civic Innovation Challenge
• Department of Defense National Security Innovation Network
• EDA University Center I-Corps Grant
• EDA Chesapeake Digital Health Exchange
• UMB Institute for Clinical & Translational Research
• Maryland Department of Commerce Anchor Ventures Sponsorship
• Maryland Department of Housing and Community Development SEED grant

DOD NATIONAL SECURITY INNOVATION NETWORK
DoD’s National Security Innovation Network (NSIN) Emerge Accelerator is a pilot program that seeks to establish partnerships with universities to develop technologies that target both government and commercial use. Funding is intended to accelerate technology development and venture formation.

UMB’s application focused on 10 existing technologies that highlight our clinical and research expertise in trauma care and training, vaccine and adjuvant development, and radiation treatment. We were one of 25 universities selected for further review. Each submitted technology received a strategic analysis of their proposed IP opportunities.

One UMB technology, a trans-esophageal aortic blood flow occluder, developed by Dr. Joseph Rabin from the UMSOM Department of Surgery, was selected for full participation. Dr Rabin and his team received assistance with identifying and marketing to military collaborators and customers as well as with the creation of a well-developed pitch deck.
UMB was awarded a third SEED grant from the Maryland Department of Housing and Community Development (DHCD) to support the development of entrepreneurial infrastructure in West Baltimore, bringing the total award to $2.25 million. The grant awards provide funding to off-set the development of flexible lab and innovation spaces in 4MLK, the UM BioPark’s new 250,000 sq. ft. mixed-use building. 4MLK is anticipated to open in summer 2024.

Innovation Hall, one of the supported initiatives, will provide civic innovation spaces—places where companies of all sizes, stages, and industries can build their businesses and connect with one another, anchor institutions, and other regional entities. Wexford Science & Technology, the developer of 4MLK, is providing the matching funds for the award.

**ANCHOR VENTURES**

**FY2022 ACCOMPLISHMENTS**

4 PROGRAMMED EVENTS  300 LIVE ATTENDEES

Anchor Ventures harnesses the collective expertise and influence of local universities, key stakeholders, entrepreneurs, and investors to foster collaboration between and the education of Baltimore’s innovation ecosystem. Led by staff from UMB and Johns Hopkins University, Anchor Ventures provided four programmed events in FY2022 and collaborated with TEDCO and Chesapeake DHX. A grant from the Maryland Department of Commerce helped support activities this year. Topics included a reverse pitch focused on innovative digital health technology, cell and gene therapy technologies and applications, advice and stories from successful student entrepreneurs, and a digital health pitch competition. Programming for FY2023 is anticipated to expand with opportunities for in person events.

**MARYLAND DHCD SEED GRANTS**

UMB was awarded a third SEED grant from the Maryland Department of Housing and Community Development (DHCD) to support the development of entrepreneurial infrastructure in West Baltimore, bringing the total award to $2.25 million. The grant awards provide funding to off-set the development of flexible lab and innovation spaces in 4MLK, the UM BioPark’s new 250,000 sq. ft. mixed-use building. 4MLK is anticipated to open in summer 2024.

Innovation Hall, one of the supported initiatives, will provide civic innovation spaces—places where companies of all sizes, stages, and industries can build their businesses and connect with one another, anchor institutions, and other regional entities. Wexford Science & Technology, the developer of 4MLK, is providing the matching funds for the award.
UM VENTURES

Since the inception of UM Ventures in 2012, there has been a dramatic increase in technology transfer activities at both UMB and UMCP. The 10-year trend is reflected in the following graphic.

In FY2022, UM Ventures recorded 308 new disclosures, 50 licenses, and created 12 new startups. In addition, six new products made it to market, 79 patent applications were filed, and 85 patents were issued.

Through the concerted efforts of UM Ventures staff, strategic industry partnerships have been strengthened and the startup portfolio includes more high-profile startups.
UMB’s Office of Technology Transfer (OTT) team works with leading UMB surgeons to expand the development of novel medical devices and grow UMB’s medical device portfolio. Collaboration with the UMSOM supported development of a medical device innovation and rapid prototyping lab. The space is located within the UMSOM to facilitate easy access for surgeons working in the hospital. UMB’s OTT team and the Fischell Institute provide direct support enabling CAD drawings, 3D printing, rapid prototyping, and streamlined patent filing.

Since the lab’s creation:
- Eleven device projects have been created by UMSOM faculty.
- Three startups have been formed around projects: Lionheart, Protaryx, and Econnect-1.

FY2022 activities included:
- A medical device design challenge was launched to foster the disclosure of additional potential device development projects.
- Approval was granted to hire a new full time staff person to augment medical device development (expected to hire in early FY2023).

**LIFETIME ACCOMPLISHMENTS**

- 11 PROJECTS CONDUCTED
- 5 PATENT APPLICATIONS FILED
- 3 STARTUPS CREATED
CDHX @UMB DIGITAL HEALTH PRE-ACCELERATOR

UMB collaborated with the Chesapeake Digital Health Exchange to develop and deliver a digital health pre-accelerator to 18 UMB faculty and staff as part of a regional EDA grant. Over six sessions, the program covered topics critical to the successful commercialization of digital health technologies, products, and services. Each session included tailored lectures and rich panel discussions. Lectures were delivered by well-respected experts in medical device commercialization. Additional experienced entrepreneurs and innovators shared their insights and experiences during panel discussions. The program was well-received by all participants and is helping expand digital health technology commercialization at UMB.

MEDICAL DEVICE DEVELOPMENT FUND

The Medical Device Development Fund launched in October 2018 with the purpose of advancing medical device technologies toward commercialization. Building upon existing resources, such as the Robert E. Fischell Institute for Biomedical Devices, the Fund leverages UMB and UMCP’s strengths in medical device development to rapidly contribute to human health related innovation and commercial products.

Thus far there have been 14 awards at $50,000 each with three projects funded in FY2022 supporting joint research. Projects included:

- Porous gels that can rapidly absorb blood utilizing advanced materials for hemostatic applications. Funds will provide additional data to prove efficacy. Commercialization plans are to license the technology to an existing UMB startup company.
- Thermally responsive alkane partitions for point-of-care diagnostics which allow for sophisticated assays to be performed outside of a central lab and in a timely manner. Funds will be utilized to develop a fully-functional and automated prototype that will further discussions with interested investors and licensees.
- A knee osteoarthritis insole that would provide biofeedback to clinicians to assess the risk of knee osteoarthritis in a patient. Funds will be used to collect clinical data. The technology is planned to be the basis of a new startup company.

Medical Device Development Fund
LIFE SCIENCES IP FUND

The Life Sciences IP Fund, created in February 2018, provides proof-of-concept and external validation funding to accelerate commercialization of technologies at UMB. Supported projects receive project management support along with funding for technology validation and further development. Five projects have resulted in the creation of new UMB startups: Isoprene Pharmaceuticals, Protaryx, GEn1E Lifesciences, E-connect, and RenuBioMed. Protaryx and GEn1E have successfully closed initial financing rounds, and in mid-2021, Isoprene received a $2 million SBIR Direct-to-Phase II grant from the National Cancer Institute. Life Science IP Fund investments have led to an additional $15 million in catalyzed (third-party) capital, a 15:1 return on investment.

LIFETIME ACCOMPLISHMENTS

15:1 ROI
5 STARTUPS FORMED
26 EARLY-STAGE TECHNOLOGIES ASSISTED

INSTITUTE FOR CLINICAL & TRANSLATIONAL RESEARCH

Institute for Clinical & Translational Research (ICTR), UMB’s first Universitywide interdisciplinary hub for clinical translational research and training, operates as part of a consortium with JHU. UMB’s OTT team works closely with the UMSOM on ICTR and provides a joint program manager to facilitate identifying promising new technologies. In addition to annual funding, in FY2022, CMAV supported patient-oriented research and Phase II clinical trials through ICTR.

A total of 13 projects were funded in FY2022.

ATIP Program of ICTR

In FY2022, ICTR created the Accelerated Translation Incubator Pilot (ATIP) program to support innovative, translational research projects.

• 23 applications received and 13 funded for a total of $451,650
• Participation from all seven UMB schools and 23 out of 24 UMSOM departments
• Collaborations across all UMB schools, UMCP, UMBC, and non-USM institutions

LIFETIME ACCOMPLISHMENTS

40% PROJECTS HAVE RESULTED IN IP DISCLOSURES
VALUE OF LICENSED TECHNOLOGIES

It is difficult and highly speculative to value technologies when they are first licensed; however, technology transfer revenues to UM Ventures have averaged $4.1 million over the past five years.

UMB Investment Portfolio
External investment is a good indicator of the value of our technologies and the strength of our companies. To date, UMB has invested $1.4 million in the most promising UMB startups, and those companies have received $86.8 million in follow-on capital investments.

TOTAL CAPITAL | $86.8M

<table>
<thead>
<tr>
<th>CO-FUNDING</th>
<th>FOLLOW-ON CAPITAL</th>
<th>AWARDED GRANTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>$26.3M</td>
<td>$46.4M</td>
<td>$14.1M</td>
</tr>
</tbody>
</table>
FY2022

ACCOMPLISHMENTS AND RECOMMENDATIONS
FY2022 SUMMARY

1. Expanded programming and outreach to interested USM faculty, staff, and students on technology transfer opportunities and to develop entrepreneurial skills.
2. Provided direct support to entities affiliated with UMB, UMCP, UMBC, UMES, UMGC, Towson, Coppin and University of Baltimore.
3. Supported UMCP I-Corps programming at Morgan State, University of Baltimore, and Coppin State, which has brought additional resources to Baltimore City and expanded the entrepreneurial capabilities of these institutions while reaching a more diverse population.
4. Advocated for and received USM Board of Regents approval to expand the USM allocation for the Maryland Momentum fund by $6 million.
5. Based on CMAV’s success, obtained an additional $2.5 million for FY2023 and received BOR approval to expand the Baltimore Fund to make equity investments.
6. Negotiated 38 licensing amendments (3x more than typical) to support delayed milestones, reduced payments, and revised business plans as a consequence of COVID impacts.

RECOMMENDATIONS FOR FY2023

1. Strengthen connections with local angel networks and national venture capital companies
2. Continue to expand outreach to and inclusion of underserved populations in activities
3. Create additional opportunities and programs to educate interested USM faculty, staff, and students on technology transfer commercialization and entrepreneurial skills.
4. Enhance support of USM affiliated early stage companies.
5. Create more collaborative programming with other USM institutions and pursue additional external funding opportunities.
6. Work closely with School of Medicine leadership to develop cohesive support programs to increase new faculty startups.
7. Develop additional technology accelerator programs to support new startups in areas including drug development, software, antibodies, and more.
8. Plan and develop programming for CMAV-supported space in 4MLK, the BioPark’s new development project.